After the panel presentation, “The Controversial QALY: Is There a Middle Ground in the Debate?” was wrapped up at ISPOR, AJMC deputy editor, Jaime Rosenberg, sat down with IVI's Jennifer Bright and Lou Garrison (assistant [...]
IVI launches a new research brief series to present research findings and method insights from the OSVP. Let’s sparks a conversation into next-gen value assessment. Read the full press release here.
IVI's Lead Scientific Advisor and Lead Economist for the Open-Source Value Platform (OSVP), Jeroen Jansen and Devin Incerti, respectively, collaborate with Jeffery Curtis in a recent article published in the Journal of Managed Care and [...]
IVI Executive Director, Jennifer Bright, writes in Morning Consult about the differences between patient-centered and consumer-driven healthcare. Read the full article here.
IVI’s Jennifer Bright the president of the Institute for Integrated Benefits, Tom Parry, Ph.D., write in Fierce Healthcare that most employers have no idea how their benefit programs affect employee health outcomes. They outline a [...]
IVI's Director of Scientific Communications, Mark Linthicum, sits down with the Journal of Clinical Pathways for a webinar discussion about IVI's open-source model for assessing value in non-small cell lung cancer therapies. If you want to [...]
IVI will host two upcoming webinars focused on its new disease-specific, open-source value model to assess EGFR+ non-small cell lung cancer (NSCLC) therapy sequences. These webinars are free and open to the public. We hope [...]
IVI released our initial version of the new Open-Source Value Platform (OSVP) model for non-small cell lung cancer. Specifically, the model provides information on the relative value of sequential treatments for epidermal growth factor receptor [...]